74,286 Shares in LENZ Therapeutics, Inc. $LENZ Bought by Aberdeen Group plc

Key Points

• Aberdeen Group plc acquired a new stake in LENZ Therapeutics, purchasing 74,286 shares valued at approximately $2,177,000, representing about 0.26% ownership of the company.
• Analyst ratings on LENZ Therapeutics are mostly positive, with five analysts issuing a Buy rating and a consensus target price of $52.80, while Weiss Ratings maintained a Sell rating.
• LENZ Therapeutics reported a quarterly EPS of ($0.53), slightly beating analyst estimates, with a revenue of $5.00 million for the quarter.

Aberdeen Group plc purchased a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 74,286 shares of the company's stock, valued at approximately $2,177,000. Aberdeen Group plc owned about 0.26% of LENZ Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Banque Transatlantique SA acquired a new position in shares of LENZ Therapeutics during the first quarter valued at about $119,000. GAMMA Investing LLC grew its position in LENZ Therapeutics by 5,254.1% during the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock worth $150,000 after purchasing an additional 5,727 shares during the last quarter. AlphaQuest LLC acquired a new position in LENZ Therapeutics during the 1st quarter valued at approximately $168,000. Westfield Capital Management Co. LP purchased a new position in shares of LENZ Therapeutics in the first quarter worth $261,000. Finally, Swiss National Bank lifted its stake in shares of LENZ Therapeutics by 12.7% during the first quarter. Swiss National Bank now owns 21,300 shares of the company's stock worth $548,000 after buying an additional 2,400 shares during the period. Institutional investors and hedge funds own 54.32% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on LENZ. Raymond James Financial upped their target price on LENZ Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of LENZ Therapeutics in a research note on Wednesday, October 8th. Citigroup reissued a "buy" rating and issued a $49.00 price objective (up from $45.00) on shares of LENZ Therapeutics in a report on Thursday, July 31st. HC Wainwright lifted their target price on LENZ Therapeutics from $38.00 to $48.00 and gave the stock a "buy" rating in a report on Monday, July 28th. Finally, Piper Sandler increased their price target on shares of LENZ Therapeutics to $67.00 and gave the stock an "overweight" rating in a report on Friday, October 10th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, LENZ Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $52.80.

LENZ Therapeutics Trading Down 5.4%

Shares of NASDAQ:LENZ opened at $38.26 on Friday. LENZ Therapeutics, Inc. has a 12-month low of $16.53 and a 12-month high of $50.40. The business has a 50 day moving average of $41.15 and a two-hundred day moving average of $32.94. The company has a market capitalization of $1.09 billion, a PE ratio of -20.14 and a beta of 0.50.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.05. The firm had revenue of $5.00 million for the quarter, compared to analyst estimates of $5.00 million. Equities research analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.